Bhagirathbhai Dholaria, MBBS, on Progress With CAR T in Blood Cancers and Addressing RelapsesApril 11th 2023
The assistant professor of medicine at Vanderbilt University Medical Center discussed the work that has been done in the field in the past 10 years and work that still remains to be done.
Tabelecleucel Demonstrates Efficacy, Safety in Phase 3 Trial for EBV-positive Post-transplant Lymphoproliferative DiseaseFebruary 16th 2023
Among 43 patients who had EBV+ PTLD following allogeneic hematopoietic cell transplant or solid organ transplant, the overall response rate was 51.2%.
T-allo10 Cell Infusion After Haploidentical HSCT Is Safe, Well-Tolerated, Prelim Data ShowApril 25th 2022
The treatment seeks to improve immune reconstitution and graft-versus-leukemia immune response without increasing the risk of GvHD in children and young adults with hematologic malignancies.